^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    Oncomine™ Comprehensive Assay v3M

    Company:
    Thermo Fisher Scientific
    Type:
    Laboratory Developed Test
    Related tests:
    Evidence Level:
    Sensitive: C4 – Case Studies

    [EML4-NTRK3 fusion-Lung Adenocarcinoma-entrectinib]

    Source:
    Front Oncol
    Test:

    Oncomine™ Comprehensive Assay v3M

    Title:
    Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
    Published date:
    11/07/2022
    Excerpt:
    ...we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib.
    DOI:
    https://doi.org/10.3389/fonc.2022.1038774
    Evidence Level:
    Sensitive: C4 – Case Studies

    [EGFR exon 19 deletion + ATM S1455fs*36 + MYC E62K-Lung Adenocarcinoma-erlotinib]

    Source:
    IASLC-WCLC 2022
    Test:

    Oncomine™ Comprehensive Assay v3M

    Title:
    EP08.02-075 - Maintained Complete Response for 8+ Years with Erlotinib Alone in Advanced Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion
    Published date:
    07/12/2022
    Excerpt:
    A 59-year old female...Cytologic material obtained by EBUS-FNA of stations 4R, 4L, and 11R, revealed metastatic pulmonary adenocarcinoma….Oncomine™ Comprehensive Assay v.3 in February 2022 revealed the following mutations: EGFR p.L747_A750delinsP (i.e., the known ex19del, now more specified), ATM p.S1455fs*36, most likely a loss-of-function mutation, and the rare pathogenic MYC variant c.184G>A, p.E62K....The patient initiated Erlotinib 150 mg daily in March 2014, obtained a partial response by June 2014, and gradually reached complete remission (CR) in May 2015. The CR has persisted ever since (latest CT scan in February 2022).